Intra-arterial PSMA injection using hepatic arterial infusion pump in intrahepatic cholangiocarcinoma: a proof-of-concept study.
Humans
Cholangiocarcinoma
/ diagnostic imaging
Positron Emission Tomography Computed Tomography
/ methods
Bile Duct Neoplasms
/ diagnostic imaging
Male
Middle Aged
Aged
Gallium Radioisotopes
/ administration & dosage
Hepatic Artery
/ diagnostic imaging
Proof of Concept Study
Gallium Isotopes
Injections, Intra-Arterial
Female
Infusions, Intra-Arterial
Oligopeptides
/ administration & dosage
Feasibility Studies
Infusion Pumps
Radiopharmaceuticals
/ administration & dosage
Cholangiocarcinoma
Gallium 68 PSMA-11
Injections (intra-arterial)
Positron emission tomography-computed tomography
Precision medicine
Journal
European radiology experimental
ISSN: 2509-9280
Titre abrégé: Eur Radiol Exp
Pays: England
ID NLM: 101721752
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
01
05
2024
accepted:
05
07
2024
medline:
2
8
2024
pubmed:
2
8
2024
entrez:
1
8
2024
Statut:
epublish
Résumé
Prostate-specific membrane antigen (PSMA) targeted tracers show increased uptake in several malignancies, indicating a potential for peptide radioligand therapy. Intra-arterial injection of radiotracers can increase the therapeutic window. This study aimed to evaluate the feasibility of intra-arterial injection of [
Identifiants
pubmed: 39090480
doi: 10.1186/s41747-024-00496-4
pii: 10.1186/s41747-024-00496-4
doi:
Substances chimiques
Gallium Radioisotopes
0
gallium 68 PSMA-11
0
Gallium Isotopes
0
Oligopeptides
0
Radiopharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
90Informations de copyright
© 2024. The Author(s).
Références
de Galiza Barbosa F, Queiroz MA, Nunes RF et al (2020) Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging 20:23. https://doi.org/10.1186/s40644-020-00300-7
doi: 10.1186/s40644-020-00300-7
pubmed: 32169115
pmcid: 7071711
Kinoshita Y, Kuratsukuri K, Landas S et al (2006) Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 30:628–636. https://doi.org/10.1007/s00268-005-0544-5
doi: 10.1007/s00268-005-0544-5
pubmed: 16555021
Bergquist A, von Seth E (2015) Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol 29:221–232. https://doi.org/10.1016/j.bpg.2015.02.003
doi: 10.1016/j.bpg.2015.02.003
pubmed: 25966423
Antwi SO, Mousa OY, Patel T (2018) Racial, Ethnic, and Age Disparities in Incidence and Survival of Intrahepatic Cholangiocarcinoma in the United States; 1995-2014. Ann Hepatol 17:604–614. https://doi.org/10.5604/01.3001.0012.0929
doi: 10.5604/01.3001.0012.0929
pubmed: 29893702
Chen W, Lee Z, Awadallah A, Zhou L, Xin W (2020) Peritumoral/vascular expression of PSMA as a diagnostic marker in hepatic lesions. Diagn Pathol 15:92. https://doi.org/10.1186/s13000-020-00982-4
doi: 10.1186/s13000-020-00982-4
pubmed: 32703222
pmcid: 7376868
Thompson SM, Suman G, Torbenson MS et al (2022) PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68) Ga-PSMA-11 PET Using Cyclotron-Produced (68) Ga. Hepatol Commun 6:1172–1185. https://doi.org/10.1002/hep4.1861
doi: 10.1002/hep4.1861
pubmed: 34783177
Chahinian R, El-Amine A, Matar S, Annan M, Shamseddine A, Haidar M (2020) (68)Ga-Prostate-Specific Membrane Antigen, A Potential Radiopharmaceutical in PET/CT To detect primary Cholangiocarcinoma. Asia Ocean J Nucl Med Biol 8:136–140. https://doi.org/10.22038/AOJNMB.2020.46939.1314
doi: 10.22038/AOJNMB.2020.46939.1314
pubmed: 32715002
pmcid: 7354244
Alipour R, Gupta S, Trethewey S (2017) 68Ga-PSMA Uptake in Combined Hepatocellular Cholangiocarcinoma With Skeletal Metastases. Clin Nucl Med 42:e452–e453. https://doi.org/10.1097/RLU.0000000000001771
doi: 10.1097/RLU.0000000000001771
pubmed: 28806238
Kauffman N, Morrison J, O’Brien K, Fan J, Zinn KR (2023) Intra-Arterial Delivery of Radiopharmaceuticals in Oncology: Current Trends and the Future of Alpha-Particle Therapeutics. Pharmaceutics 15. https://doi.org/10.3390/pharmaceutics15041138
Hepatic arterial infusion pump chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma. Netherlands Trial Register website: https://www.trialregister.nl/trial/8234 . Accessed September 7 2023
Buisman FE, Homs MYV, Grunhagen DJ et al (2019) Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial. BMC Cancer 19:327. https://doi.org/10.1186/s12885-019-5515-6
doi: 10.1186/s12885-019-5515-6
pubmed: 30953467
pmcid: 6451273
(EANM) TEAoNM: About EARL. https://earl.eanm.org/about-earl-2/ . Accessed November 13th 2023
Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL (1999) Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 213:521–525. https://doi.org/10.1148/radiology.213.2.r99nv37521
doi: 10.1148/radiology.213.2.r99nv37521
pubmed: 10551235
Ahmadzadehfar H, Eppard E, Kurpig S et al (2016) Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget 7:12477–12488. https://doi.org/10.18632/oncotarget.7245
doi: 10.18632/oncotarget.7245
pubmed: 26871285
pmcid: 4914299
Lian Y, Zeng S, Wen S, Zhao X, Fang C, Zeng N (2023) Review and Application of Integrin Alpha v Beta 6 in the Diagnosis and Treatment of Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma. Technol Cancer Res Treat 22:15330338231189399. https://doi.org/10.1177/15330338231189399
doi: 10.1177/15330338231189399
pubmed: 37525872
pmcid: 10395192
Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674–2681
pubmed: 10537328
O’Keefe DS, Bacich DJ, Huang SS, Heston WDW (2018) A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies. J Nucl Med 59:1007–1013. https://doi.org/10.2967/jnumed.117.203877
doi: 10.2967/jnumed.117.203877
pubmed: 29674422
pmcid: 6910646